Higher-dose Exelon Patch approved for Alzheimer's

Share this article:
Higher-dose Exelon Patch approved for Alzheimer's
Higher-dose Exelon Patch approved for Alzheimer's
The Food and Drug Administration has approved a 13.3mg/24h dosage strength of the Exelon Patch for the treatment of patients with mild to moderate Alzheimer's disease. Approval was based on a 48-week double-blind phase of the OPTIMA study. The controlled trial targeted people with mild to moderate Alzheimer's. Compared to an older patch, patients treated with this higher dosage patch experienced statistically significant functional improvement.
Share this article:

More in Products

ACO white paper geared toward post-acute providers

A new white paper focuses on what kinds of services accountable care organizations should provide in the post-acute spectrum.

Accutech Security releases wander management system

Accutech Security releases wander management system

Accutech Security has released its new ResidentGuard LS 2400 wander management system, which can be used in senior living settings.

Sharps Compliance Corp. and MedReturn, LLC launch MedSafe

Sharps Compliance Corp. and MedReturn, LLC launch MedSafe

The Sharps Compliance Corp. and MedReturn LLC have created MedSafe, a system set up to dispose of unwanted and expired medications, including controlled substances.